RNS Number : 1052Z
Minster Pharmaceuticals PLC
15 September 2009
MINSTER PHARMACEUTICALS PLC
('Minster' or 'the Company')
Change of Registered Office
Minster Pharmaceuticals plc (AIM: MPM) announces that its registered office has been changed to Salisbury House, Station Road, Cambridge, Cambridgeshire, CB1 2LA, with immediate effect.
For further information:
|
Minster Pharmaceuticals plc
|
|
|
Karl Keegan, Chief Financial Officer
|
Tel: +44 (0) 20 7936 9921
|
|
Jeremy Gorman, Company Secretary
|
Tel: +44 (0) 20 7935 0027
|
|
|
|
|
Buchanan Communications
|
Tel: +44 (0) 20 7466 5000
|
|
Mark Court / Catherine Breen
|
|
|
|
|
|
Nomura Code Securities Limited
|
Tel: +44 (0) 20 7776 1200
|
|
Chris Collins / Richard Potts
|
|
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat and sabcomeline. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia and the strategy for its further clinical development is currently under consideration.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CROBSGDCCDBGGCU